Synnöve Staff

Mutations in BRIP1 confer high risk of ovarian cancer

Daníel F. Guðbjartsson, Patrick Sulem, Áslaug Jónasdóttir et al. · Nature Genetics · 2011 · 426 citations

Somatic Variant, Genetics, Cancer Genetics +2

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial

Mansoor Raza Mirza, Elisabeth Åvall Lundqvist, Michael J. Birrer et al. · The Lancet Oncology · 2019 · 239 citations

Superiority Trial, Medicine, Gynecology +8

Cesarean scar defect: a prospective study on risk factors

Riitta M. Antila-Långsjö, Johanna Mäenpää, Heini Huhtala et al. · American Journal of Obstetrics and Gynecology · 2018 · 180 citations

Cesarean Scar Defect, Gynecology, Maternal Health +5

Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells

Katri Köninki, Márk Barok, Minna Tanner et al. · Cancer Letters · 2010 · 107 citations

Multiple Molecular Mechanisms, Breast Oncology, Medicine +7

Haplo-insufficiency of BRCA1 in sporadic breast cancer.

Synnöve Staff, Jorma Isola, Minna Tanner · PubMed · 2003 · 78 citations

Breast Oncology, Genetics, Pathology +17